Cagrilintide, an amylin analog, enhances the weight loss effects of semaglutide or tirzepatide by slowing gastric emptying, suppressing glucagon, and reducing appetite. It works synergistically with Cagrilintide and tirzepatide are NOT medically equivalent, and one cannot replace the other like a refill. , Tirzepatide is FDA approved and dosed once weekly with careful titration based on Recent advances in peptide based therapies for obesity and type 2 diabetes ScienceDirect Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link